APOL1 risk variants are associated with an increased risk of chronic kidney disease. Findings from a new study demonstrate that a small molecule, inaxaplin, inhibits APOL1 channel function; furthermore, inaxaplin reduced proteinuria in patients with focal segmental glomerulosclerosis and two APOL1 risk variants.
This is a preview of subscription content, log in via an institution to check access.
References
United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States (NIH/NIDDK, 2022).
Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841–845 (2010).
Daneshpajouhnejad, P., Kopp, J. B., Winkler, C. A. & Rosenberg, A. Z. The evolving story of apolipoprotein L1 nephropathy: the end of the beginning. Nat. Rev. Nephrol. 18, 307–320 (2022).
Parsa, A. et al. APOL1 risk variants, race, and progression of chronic kidney disease. N. Engl. J. Med. 369, 2183–2196 (2013).
Chen, D. P. et al. Kidney disease progression in membranous nephropathy among Black participants with high-risk APOL1 genotype. Clin. J. Am. Soc. Nephrol. 18, 337–343 (2023).
Reeves-Daniel, A. M. et al. The APOL1 gene and allograft survival after kidney transplantation. Am. J. Transplant. 11, 1025–1030 (2011).
Olabisi, O. A. et al. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proc. Natl Acad. Sci. USA 113, 830–837 (2016).
Egbuna, O. et al. Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. N. Engl. J. Med. 388, 969–979 (2023).
Troost, J. P. et al. An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 13, 414–421 (2018).
Kopp, J. B. et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 22, 2129–2137 (2011).
Acknowledgements
R.G. is supported by NIH/NICHD 1R21HD104176-01 and NIH/NIDDK 1R01DK134347-01.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.G. is currently on the Advisory Board of Vertex Pharmaceuticals. He became a member of the Advisory Board following completion of the study and analysis of the results presented in the paper under discussion.
Rights and permissions
About this article
Cite this article
Gbadegesin, R., Lane, B. Inaxaplin for the treatment of APOL1-associated kidney disease. Nat Rev Nephrol 19, 479–480 (2023). https://doi.org/10.1038/s41581-023-00721-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-023-00721-0
- Springer Nature Limited